Oncologic Inc.
This article was originally published in Start Up
Executive Summary
Oncologic Inc. hopes to circumvent the heterogeneity of solid tumors with a multi-step process. It will target two independent cellular cancer characteristics-the presence of an endocytosing receptor, and sensitivity to a chemotherapeutic agent; then erect a novel chemical platform throughout the tumor to hold radioactive isotopes in place to kill the entire tumor, not just individual cancer cells.